hepatitis Archives

More News! 2 Jul 2018

New Blood Test Brings Cheaper Hepatitis B Diagnosis

European and African researchers are developing a hepatitis B blood test that could help identify patients in Africa’s poorest regions who need immediate treatment. While treatments for hepatitis B are now available at a low cost, managing treatments effectively is still a challenge in Africa. This is because some patients who are infected with the […]

July 2, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 19 Feb 2018

Organ-on-a-Chip Technology Used to Spot New Hepatitis B Drug Targets

Scientists in London are the first in the world to test how pathogens like the hepatitis B virus interact with artificial human organs. Researchers at Imperial College London have used artificial human organs, or organs-on-chips, to replicate the make-up and physiology of the cells in whole organs. The study, published in Nature Communications, shows how the […]

February 19, 2018 - 3 minutesmins - By Alex Dale

News and Trends 23 Oct 2017

Transgene‘s Hepatitis B Vaccine Does the Business at Phase I

The French biotech‘s hepatitis B vaccine has demonstrated good efficacy and safety, suggesting it could provide effective protection from the virus. Biotech veteran, Transgene, specializes in viral-based immunotherapies for cancers and infectious diseases. One of its targets, hepatitis B, is a potentially fatal liver infection caused by the hepatitis B virus (HBV). Today, it has […]

October 23, 2017 - 2 minutesmins - By Alex Dale

News and Trends 14 Jun 2017

French Hepatitis Cure is on Track with Positive Phase I Results

Enyo Pharma has announced that its lead candidate EYP001, indicated for the treatment of hepatitis B, successfully cleared a Phase Ia trial. Enyo Pharma is one of the hottest biotechs in Lyon that is developing new treatments against viruses, including hepatitis B or severe influenza infections. Its key asset, EYP001, is a farnesoid X receptor (FXR) agonist indicated […]

June 14, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 23 Dec 2016

The 8 Biggest Biotech Medical Fails of 2016 in Europe

Although 2016 has brought plenty of good news in medical advances, biotech is an industry where failure is part of the game. Here’s a list of medical fails in biotech to learn from this year. Unfortunately, 2016 has not been a good year for pharma, with revenues in the top companies falling, the lowest number […]

December 23, 2016 - 5 minutesmins - By Clara Rodríguez Fernández

News and Trends 4 Aug 2016

Roche drops Partnership for Hepatitis Immunotherapy

While everybody wants to get the next immunotherapy on the market, Roche is turning its back on one. It’s leaving the partnership with Inovio, which focuses on developing a DNA-based immunotherapy to treat Hepatitis B. Previously, Roche has left projects to focus on immunotherapies, particularly in the hype field of immuno-oncology. This was an important […]

August 4, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 28 Jul 2016

World Hepatitis Day 2016: What is the plan for Biotech and Policy Makers?

What is the purpose of the #NoHep campaign? To get rid of the inflammatory Liver viruses which are responsible for killing up to 1.4 million people each year, by 2030. Sometimes also described as the ‘Silent Epidemic’, Hepatitis is the inflammation of the liver, which can be caused by several types of viral infections. Research […]

July 28, 2016 - 2 minutesmins - By Dani Bancroft

abivax ceo ehrlich interview hiv hepatitis

News and Trends 4 Jul 2016

“We have one of the World’s Most Advanced Functional HIV Cures under development”

Abivax has recently announced that it’s likely that its most advanced program in hepatitis B will fail its Phase III trials. That’s really bad news for the company, and stocks have plummeted by around 50%. But what does this really mean for the future of Abivax? To find out, I had a chat with the company’s CEO Hartmut […]

July 4, 2016 - 5 minutesmins - By Denise Neves Gameiro

russia biotech hepatera maxwell mya hepatits b d phase ii b trials

News and Trends 22 Mar 2016

Biotech in Russia: Money and a New trial for Hepatitis

The Biotech MYR Pharma (Germany) is launching German-Russian phase IIb trials for chronic hepatitis B & D infections in partnership with Moscow’s Hepatera (Russia). MYR was founded in 2010 and is based in Burgwedel, Germany, supported by investors Maxwell Biotech and High-Tech Gründerfonds (HTGF). Hepatera, on the other hand, is actually the first Russian biotech we’ve encountered […]

March 22, 2016 - 2 minutesmins - By Dani Bancroft

News and Trends 15 Feb 2016

Celebrating the 10th Birthday of this German Infectious Disease Biotech with the CEO

AiCuris is a Biotech company based on the Bayer Life Sciences park in Wuppertal (Germany). It is working on new anti-infective drugs and is a former spin-off of Germany’s biggest Pharma Company. It’s celebrating its 10th birthday this year, which is good reason to interview the CEO… So AiCuris is working on anti-infective drugs for […]

February 15, 2016 - 4 minutesmins - By Philip Hemme

kuros cytos biotechnologies biosciences vaccine hepatitis merger bone biosurgeries

News and Trends 20 Jan 2016

Swiss Biotech Merger: Bones + Oncology + Vaccines?

Kuros Biosurgery in Zürich (Switzerland), the bone remodelling biotech for trauma patients, today officially acquired Cytos Biotechnology in Schlieren, the two of which are now to be rebranded ‘Kuros Biosciences’ in a Swiss Stock Exchange merger. Kuros is developing innovative products for tissue repair and regeneration. The company is a spin-off of the Swiss Federal […]

January 20, 2016 - 2 minutesmins - By Dani Bancroft

News and Trends 5 Jun 2015

Abivax launched an Euronext IPO to build up its anti-viral portfolio

Abivax has ended the paperwork and launched its IPO on Euronext Paris, where the biotech company plans to raise €43.6M. The clinical stage biotech is focused on developing anti-viral compounds and human vaccines. The French biotech want to insufflate the raised cash in its three developing products. Data from the two most advanced ones, ABX203 and ABX464, suggest that […]

June 5, 2015 - 1 minutemin - By Lourdes Riquelme

Resources

Categories

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

hepatitis

New Blood Test Brings Cheaper Hepatitis B Diagnosis

Organ-on-a-Chip Technology Used to Spot New Hepatitis B Drug Targets

Transgene‘s Hepatitis B Vaccine Does the Business at Phase I

French Hepatitis Cure is on Track with Positive Phase I Results

The 8 Biggest Biotech Medical Fails of 2016 in Europe

Roche drops Partnership for Hepatitis Immunotherapy

World Hepatitis Day 2016: What is the plan for Biotech and Policy Makers?

“We have one of the World’s Most Advanced Functional HIV Cures under development”

Biotech in Russia: Money and a New trial for Hepatitis

Celebrating the 10th Birthday of this German Infectious Disease Biotech with the CEO

Swiss Biotech Merger: Bones + Oncology + Vaccines?

Abivax launched an Euronext IPO to build up its anti-viral portfolio

Subscribe to our newsletter to get the latest biotech news!

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!